Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionWELLS FARGO VARIABLE TRUST - Wells Fargo VT Index Asset Allocation Fund Class 2
Latest Disclosed Ownership202 shares
Latest Disclosed Value $ 89,930
WELLS FARGO VARIABLE TRUST - Wells Fargo VT Index Asset Allocation Fund Class 2 reports 4.27% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On August 26, 2025 - WELLS FARGO VARIABLE TRUST - Wells Fargo VT Index Asset Allocation Fund Class 2 filed a NPORT-P form disclosing ownership of 202 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $89,930 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 211 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -4.27% during the quarter. The current value of the position is $86,525 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Vertex Pharmaceuticals EC US92532F1003 202 -9 -4.27 90 -12.75 0.1325
2025-05-27 2025-03-31 NP Vertex Pharmaceuticals EC US92532F1003 211 -7 -3.21 102 17.24 0.1541
2025-02-26 2024-12-31 NP Vertex Pharmaceuticals EC US92532F1003 218 -15 -6.44 88 -19.44 0.1256
2024-11-25 2024-09-30 NP Vertex Pharmaceuticals EC US92532F1003 233 -6 -2.51 108 -3.57 0.1494
2024-08-26 2024-06-30 NP Vertex Pharmaceuticals EC US92532F1003 239 -6 -2.45 112 9.80 0.1605
2024-05-28 2024-03-31 NP Vertex Pharmaceuticals EC US92532F1003 245 -13 -5.04 102 -1.92 0.1468
2024-02-28 2023-12-31 NP Vertex Pharmaceuticals EC US92532F1003 258 -7 -2.64 105 13.04 0.1574
2023-11-22 2023-09-30 NP Vertex Pharmaceuticals EC US92532F1003 265 -29 -9.86 92 -10.68 0.1482
2023-08-28 2023-06-30 NP Vertex Pharmaceuticals EC US92532F1003 294 2 0.68 103 11.96 0.1561
2023-05-25 2023-03-31 NP Vertex Pharmaceuticals EC US92532F1003 292 -6 -2.01 92 6.98 0.1427
2023-02-24 2022-12-31 NP Vertex Pharmaceuticals EC US92532F1003 298 -5 -1.65 86 -1.15 0.1376
2022-11-29 2022-09-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 303 -7 -2.26 88 0.00 0.1431
2022-08-29 2022-06-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 310 -4 -1.27 87 7.41 0.1330
2022-05-31 2022-03-31 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 314 -9 -2.79 82 15.71 0.1072
2022-02-28 2021-12-31 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 323 -18 -5.28 71 14.75 0.0853
2021-11-24 2021-09-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 341 -14 -3.94 62 -14.08 0.0769
2021-08-27 2021-06-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 355 -21 -5.59 72 -11.25 0.0873
2021-06-01 2021-03-31 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 376 -22 -5.53 81 -14.89 0.1018
2021-03-01 2020-12-31 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 398 -25 -5.91 94 -18.26 0.1193
2020-11-25 2020-09-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 423 -15 -3.42 115 -9.45 0.1545
2020-08-28 2020-06-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 438 25 6.05 127 29.59 0.1785
2020-05-28 2020-03-31 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 413 -9 -2.13 98 6.52 0.1538
2020-02-28 2019-12-31 NP VERTEX PHARMACEUTICALS INC USD.01 EC 92532F100 422 -27 -6.01 92 21.05 0.1279
2019-11-26 2019-09-30 NP VERTEX PHARMACEUTICALS INC USD.01 EC US92532F1003 449 449 76 0.1054
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.